- Home
- TAIT vs PHGE Comparison
TAIT vs PHGE Comparison
Compare TAIT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAIT
- PHGE
- Stock Information
- Founded
- TAIT 1989
- PHGE 2015
- Country
- TAIT United States
- PHGE Israel
- Employees
- TAIT N/A
- PHGE N/A
- Industry
- TAIT Electronic Components
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- TAIT Technology
- PHGE Health Care
- Exchange
- TAIT Nasdaq
- PHGE Nasdaq
- Market Cap
- TAIT 13.3M
- PHGE 11.0M
- IPO Year
- TAIT 1995
- PHGE N/A
- Fundamental
- Price
- TAIT $2.18
- PHGE $0.46
- Analyst Decision
- TAIT
- PHGE Strong Buy
- Analyst Count
- TAIT 0
- PHGE 1
- Target Price
- TAIT N/A
- PHGE $15.00
- AVG Volume (30 Days)
- TAIT 16.6K
- PHGE 271.1K
- Earning Date
- TAIT 08-13-2025
- PHGE 08-13-2025
- Dividend Yield
- TAIT 9.21%
- PHGE N/A
- EPS Growth
- TAIT N/A
- PHGE N/A
- EPS
- TAIT 0.01
- PHGE N/A
- Revenue
- TAIT $4,260,000.00
- PHGE N/A
- Revenue This Year
- TAIT N/A
- PHGE N/A
- Revenue Next Year
- TAIT N/A
- PHGE N/A
- P/E Ratio
- TAIT $225.79
- PHGE N/A
- Revenue Growth
- TAIT N/A
- PHGE N/A
- 52 Week Low
- TAIT $2.01
- PHGE $0.34
- 52 Week High
- TAIT $3.05
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- TAIT 47.75
- PHGE 44.42
- Support Level
- TAIT $2.15
- PHGE $0.45
- Resistance Level
- TAIT $2.28
- PHGE $0.51
- Average True Range (ATR)
- TAIT 0.07
- PHGE 0.05
- MACD
- TAIT 0.00
- PHGE 0.01
- Stochastic Oscillator
- TAIT 28.00
- PHGE 55.56
About TAIT Taitron Components Incorporated
Taitron Components Inc is a supplier of originally designed and manufactured (ODM) products that include value-added engineering and turn-key solutions. It focuses on providing original equipment manufacturers (OEMs) and contracts electronic manufacturers (CEMs) with ODM products for their multi-year turn-key projects and ODM electronic components. The company's product offerings range from discrete semiconductors to small electronic devices. The company also distributes brand-name electronic components with a vast inventory available on hand. Its Taiwan and China locations, provide support for inventory sourcing, purchases, and coordinating the manufacture of ODM Projects and ODM Components.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).